Zhaozu Feng

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China

Publications

• Research Article   
  Carfilzomib Triggers Endoplasmic Reticulum Stress By Up-Regulating the PERK-eIf2? Pathway in Uterine Corpus Endometrial Carcinoma Cells
  Author(s): Zhaozu Feng, Ke Wang, Yunfeng Ma and Wenjuan Luo*
  
  Uterine corpus endometrial carcinoma is one of the most common female pelvic malignancies. Carfilzomib, a second-generation Proteasome Inhibitor (PI), is currently being used for the treatment of multiple myelomas by inhibiting the pathways of IRE1-XBP1 and PERK-eIf2α. However, when used to treat solid tumors, carfilzomib activated the XBP1-IRE1 pathway without affecting PERK-eIf2α. This study aimed to elucidate the function of carfilzomib in UCEC cells and to uncover the influence of PIs on specific cancer cells. Here, two cell lines were treated with carfilzomib, and cell viability, and protein and gene expressions were evaluated. In addition, tumor-carrying BALB/c immunodeficint mice were treated with carfilzomib with or without UMI-77 supplementation, and tumor growth was analyzed. We found that Carfilzomib treatment increased apoptosis and the expression of ER st.. Read More»
  10.54608.annalsmedical.2023.83